medicinal charcoal
Botanicalexperimental
D&C Black #2 is the name, given by the FDA, for a highly pure form of carbon black prepared by combusting aromatic petroleum oil in the "oil furnace" process. It consists, essentially, of pure carbon. The Cosmetic, Toiletries and Fragrance Association (CTFA) petitioned the U.S. Food and Drug Administration (FDA) for approval to use carbon black in cosmetic formulations. The FDA granted approval on August 29, 2004, and now D&C Black #2 is used in all cosmetic products: mascaras, eyeliners, brush-on-brow, eyeshadows, and lipsticks. — NCATS
Clinical trial activity
41 trials · 36 clinical orgs · 0 marketing orgs
Phase 1
21
Phase 2
14
Phase 3
7
Phase 4
4
Earliest trial started Mar 1, 1995 (NCT00019006)
Timeline
Indications
Approved for
Studied for
- Asthma · Phase 1
- Breast Diseases · Phase 3
- Breast Neoplasms · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Cerebral Infarction · Phase 4
- Chronic Kidney Disease-Mineral and Bone Disorder · Phase 2
- Colonic Neoplasms · Phase 1
- Colorectal Neoplasms · Phase 1
- Decontamination · Phase 4
- Diabetes Mellitus, Type 2 · Phase 1
- Drug Overdose · Phase 4
- Fecal Incontinence · Phase 3
- Healthy Volunteers · Phase 1
- Hemodialysis, Home · Phase 2
- Hemorrhage · Phase 4
- Kidney Failure, Chronic · Phase 2
- Lung Neoplasms · Phase 2
- Major Depressive Disorder · Phase 1
- Melanoma · Phase 3
- Multiple Sclerosis · Phase 3
- Pancreatic Neoplasms · Phase 1
- Pharmacokinetics · Phase 1
- Pruritus · Phase 2
- Pulmonary Disease, Chronic Obstructive · Phase 2
- Renal Insufficiency, Chronic · Phase 2
- Sleep Initiation and Maintenance Disorders · Phase 1
- Small Cell Lung Carcinoma · Phase 1
- Therapeutic Equivalency · Phase 1
- Uremic Toxins · Phase 2/Phase 3
Mechanism of action
- MAP kinase p38 alphaINHIBITOR
MAPK14 inhibitor
- Thromboxane-A synthaseINHIBITOR
Thromboxane-A synthase inhibitor
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)/C=C/c1ccc(Cn2ccnc2)cc1- Mol. weight
- 12.0107 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- NCATS2P3VWU3H10 ↗
- ChEMBLCHEMBL3544968 ↗
- ChEMBLCHEMBL2106049 ↗
- ChEMBLCHEMBL11662 ↗
Also known as
- 2-propenoic acid, 3-(4-(1h-imidazol-1-ylmethyl)phenyl)-, (e)-
- 3-(4-(1h-imidazol-1-ylmethyl)phenyl)-2-propenoic acid
- 4-(1-imidazoylmethyl)cinnamic acid
- activated carbon
- activated carbon
- activated charcoal
- activated charcoal
- activated charcoal
- carbo activates
- carbo activates
- carbo activatus
- carbon
- carbon
- carbon, activated
- carbon, activated
- carbon, decolorizing
- carbon, medicinal
- carbosylane
- carbo vegetabilis
- charcoal
- charcoal
- charcoal
- charcoal activated
- charcoal activated
- charcoal-activated
- charcoal-activated
- charcoal,activated
- charcoal,activated
- charcoal, activated
- charcoal, activated
- charcoal, activated
- detox-b
- domenan
- gsk610677
- gsk610677
- gsk610677
- gsk-610677
- medicinal carbon
- medicinal carbon
- medicinal charcoal
- medicinal charcoal
- medicinal charcoal
- oky 046
- oky-046
- oky-046
- ozagrel
- ozagrel
- ozagrel
- ozagrel
- ozagrel
- ozagrel
- ozagrel hcl
- ozagrel hydrochloride
- ozagrel hydrochloride hydrate
- ozagrel, monohydrochloride
- ozagrel, monohydrochloride, (e)-isomer
- ozagrel sodium
- ozagrel sodium
- ozagrel sodium
- ozagrel sodium
- pulmoza
- sodium ozagrel
- sodium ozagrel
- sodium ozagrel
- sodium ozagrel
- xanbon
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07201311 | Phase 2 | Nov 30, 2025 | Assistance Publique - Hôpitaux de Paris |
| NCT06906874 | Phase 2 | Aug 31, 2025 | Mansoura University |
| NCT06579066 | Phase 2 | Sep 30, 2024 | Ain Shams University |
| NCT06595121 | Phase 1 | Aug 13, 2024 | Unither Pharmaceuticals |
| NCT06141473 | Phase 3 | Dec 13, 2023 | Sanofi |
| NCT05471479 | Phase 4 | Jun 1, 2023 | Laval University |
| NCT06219967 | Phase 4 | Jan 4, 2023 | State University of New York, Syracuse |
| NCT05540431 | Phase 2/Phase 3 (Phase 3) | Sep 25, 2022 | Kufa University |
| NCT05320094 | Phase 1 | Apr 15, 2022 | Bristol-Myers Squibb |
| NCT04767776 | Phase 1 | Feb 28, 2022 | University of Lyon |
| NCT04928950 | Phase 2 | Jan 31, 2022 | University of Minnesota |
| NCT04856098 | Phase 1 | May 7, 2021 | Orion Corporation |
| NCT04606329 | Phase 3 | Jul 20, 2020 | Hanlim Pharm. Co., Ltd. |
| NCT04311645 | Phase 2 | Apr 1, 2020 | Assiut University |
| NCT04204772 | Early Phase 1 (Phase 1) | Mar 31, 2020 | University of Minnesota |
| NCT04255277 | Phase 1 | Feb 29, 2020 | Idorsia Pharmaceuticals Ltd. |
| NCT04124094 | Phase 1 | Oct 1, 2019 | BECRO Ltd., Respirent Pharmaceuticals Co Ltd., University of Thessaly |
| NCT03894280 | Phase 1 | Mar 12, 2019 | BECRO Ltd., Respirent Pharmaceuticals Co Ltd., University of Thessaly |
| NCT03776448 | N/A | Jan 31, 2019 | Sulaiman Al-Rajhi Colleges |
| NCT03802487 | Phase 1 | Jan 14, 2019 | Sanofi |
Showing 20 of 41 trials
Page 1 / 3
Organizations
Research & Development (36)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Orion Corporation | For profit | 4 | 4 | 1 | 2012 |
| Eli Lilly | For profit | 3 | 3 | 1 | 2010 |
| GlaxoSmithKline | For profit | 3 | 3 | 2 | 1996 |
| Sanofi | For profit | 3 | 3 | 2 | 2013 |
| BECRO Ltd. | For profit | 2 | 0 | 1 | 2019 |
| Hanlim Pharm. Co., Ltd. | For profit | 2 | 2 | 2 | 2018 |
| Respirent Pharmaceuticals Co Ltd. | For profit | 2 | 2 | 1 | 2019 |
| University of Minnesota | Academic/Hospital | 2 | 2 | 2 | 2020 |
| University of Thessaly | Academic/Hospital | 2 | 0 | 1 | 2019 |
| Ain Shams University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Assiut University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Bristol-Myers Squibb | For profit | 1 | 1 | 1 | 2022 |
| Cascadian Therapeutics Inc. | For profit | 1 | 1 | 1 | 1999 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Federation of National Public Service Personnel Mutual Aid Associations Tachikawa Hospital | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Grunenthal | For profit | 1 | 1 | 1 | 2004 |
| Idorsia Pharmaceuticals Ltd. | For profit | 1 | 1 | 1 | 2020 |
| Kufa University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Laval University | Academic/Hospital | 1 | 1 | 1 | 2023 |
36 organizations
Page 1 / 2